OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathy – Yahoo Finance


OTT166 is a potential first-in-class non-invasive selective RGD integrin inhibitor, delivered as eye drop, for the treatment of diabetic retinopathy
OTT166 has the potential to address an unmet need for an earlier, non-invasive ophthalmic treatment for diabetic retinopathy
BOSTON, August 02, 2022–(BUSINESS WIRE)–OcuTerra Therapeutics, Inc. ("OcuTerra"), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of "watch-and-wait" does not prevent or control the progression of disease, today announced the first patient was dosed in its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy with minimal vision loss. OTT166 is a novel small molecule selective integrin inhibitor that is designed with purpose engineering to have the required physiochemical characteristics to be able to reach the retina from eye drop application.
"The initiation of the DR:EAM clinical trial marks an important milestone in our efforts to develop potentially the first, topical eye drop treatment for diabetic retinopathy," said Kerrie Brady, Chief Executive Officer and President of OcuTerra Therapeutics. "OTT166 has demonstrated tolerability and promising evidence of biological activity in patients in a Phase 1b clinical trial and we believe that it has the potential to dramatically change the treatment paradigm by enabling earlier, non-invasive, active treatment for patients with diabetic retinopathy if approved."
OTT166 has been specifically designed to be administered as an eye drop by the patient at home before diabetic retinopathy has advanced to a vision-threatening complication, such as diabetic macular edema. By potentially enabling earlier non-invasive treatment, OcuTerra’s goal is to prevent progression, thereby delaying or completely eliminating the need for intravitreal injections and/or destructive laser procedures.
"I have been dedicated to providing treatment options for patients with retinal diseases and am honored to be the Principal Investigator for the DR:EAM clinical trial to evaluate the potential of topical OTT166 in our patients with diabetic retinopathy," said Carl Regillo, M.D., Director, Retina Service, Wills Eye Hospital, Professor of Ophthalmology, Thomas Jefferson University, Philadelphia, PA. "OTT166 is an investigational integrin inhibitor that is designed to reach the retina via topical administration and represents a potential advancement in how diabetic retinopathy is treated. With its proposed mechanism of action and non-invasive delivery, OTT166 may provide an exciting option for diabetic retinopathy patients and possibly help prevent or slow disease progression. It is gratifying to see the first patient dosed in the DR:EAM study."
About the DR:EAM Clinical Trial
DR:EAM is a multicenter, randomized, double-masked clinical trial designed to assess the safety and efficacy of a high and low dose of daily topical administration of OTT166 versus placebo for 24 weeks in approximately 200 adult patients with moderately severe to severe NPDR or mild proliferative diabetic retinopathy with minimal vision loss. The primary efficacy endpoint of the clinical trial is the percentage of patients that have a 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS). Additional endpoints of the clinical trial include measuring the prevention of progression to vision-threatening complications, amount of delayed time to intravitreal injection and/or laser treatment, and exploratory imaging endpoints. More information about this trial is available at ClinicalTrials.gov.
About Diabetic Retinopathy
Diabetic retinopathy is the most common diabetic eye disease and the leading cause of vision loss and blindness in American working age adults, which affects over 8 million people in the US1. The current standard of care for diabetic retinopathy is active surveillance or "watch-and-wait"2 until a sight threatening complication arises. When vision deteriorates further due to complications, the patient must undergo injections of medication directly into the back of their eye (intravitreal injection) or undergo destructive laser procedures to help stop the growth of new blood vessels and decrease fluid buildup.
About OTT166
OTT166 is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, OTT166 selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, OTT166 eye drops have demonstrated preliminary evidence of tolerability and biological activity.
About OcuTerra Therapeutics
OcuTerra Therapeutics, Inc. is developing innovative drugs for ophthalmic diseases for which the current standard of care does not prevent or control the progression of disease. Our initial therapeutic candidate, OTT166, administered as an eye drop containing a novel, potent and selective integrin-inhibitor, is in clinical development as an early, non-invasive intervention for diabetic retinopathy, a chronic, progressive disease that is one of the leading causes of vision loss globally. Our goal is to bring transformative treatments to patients and their clinicians who are currently consigned to watch and wait as disease progresses, ultimately requiring medically intensive and invasive therapy. www.ocuterratx.com
1 Market Scope, Retinal Pharmaceuticals Market Report, 2021
2 American Academy of Ophthalmology: Preferred Practice Pattern for Diabetic Retinopathy, 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005193/en/
Contacts
MacDougall Advisors
Nicholas Chang
[email protected]
(781) 235-3060
Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success. And there are no stocks that better embody both sides – the risk factors and the reward potentials – than penny stocks. These equities, priced below $5 per share, typically offer high upside potentials. Even a small gain in share price – just a few cents – quickly translates into a high yield return. Of course, the risk is real, too; not every penny stock is going to show th
Shares of Bavarian Nordic, the company that produces the vaccine for the quickly spreading virus, are up more than 30% so far this year.
The biotech's results and what management has to say about its plans will help to determine whether a rally will continue.
The company plans to launch a clinical trial of another drug in combination with a drug developed by its CEO's former company.
When a large patch of skin is injured or missing, surgeons often turn to a skin graft. A skin graft takes a device that looks like an apple peeler, removes a healthy patch of skin from a patient's body, and implants it onto the wounded area. Avita Medical wants to replace this older system with a simpler, more cost-effective procedure.
Dietitians break down if brown rice is healthier than white rice, and how to make your bowl extra nutritious no matter which option you choose.
The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple.
Three-year-old twins Bernardo and Arthur Lima underwent seven operations at a hospital in Brazil.
CHATTANOOGA, Tenn. — Madison Underwood was lying on the ultrasound table, nearly 19 weeks pregnant, when the doctor came in to say her abortion had been canceled. Nurses followed and started wiping away lukewarm sonogram gel from her exposed belly as the doctor leaned over her shoulder to speak to her fiance, Adam Queen. She recalled that she went quiet, her body went still. What did they mean, they couldn’t do the abortion? Just two weeks earlier, she and her fiance had learned her fetus had a
The Justice Department on Tuesday sued the state of Idaho in its first formal attempt to push back, legally, against the Supreme Court’s decision to overturn Roe v. Wade.
While 28 million Americans live with alcohol use disorder, less than 8% receive treatment for their disease. Board-certified addiction specialist Sarah Akerman shares her expertise on the barriers …
From the Arctic to the Tibetan Plateau, rain water is ‘unsafe to drink’ under current PFAS guidelines
“What are you reading, Mom?” my 11-year-old son asked, bounding toward me and nosing under my arm to peer at my phone screen, at which I was scowling. He is eerily good at taking my emotional temperature, the…
Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors – BDX, PDCO and SDC.
India has the largest number of stunted children – and now a growing population of obese children.
Story at a glance A nasal vaccine could be another weapon in the arsenal against COVID-19. Early research has shown promising results in terms of efficacy. Recent research published in Science Immunology suggests coupling mRNA vaccines with an intranasal booster vaccine can provide much stronger protection against the virus in the airways where enters the…
An increasing number of studies suggest that choosing a Diet Coke instead of a Coca-Cola to trim some calories is not necessarily making a healthier choice. While many artificially sweetened beverages contain zero calories, drinking them regularly may put you at risk for health complications typically associated with being overweight, namely, metabolic disorders like cardiovascular disease.Although artificial sweeteners like aspartame (one of the more popular ingredients in diet soda) are approv
A decline in sensory functions can often be an early sign of Alzheimer’s. Hence, it’s important to lower your risk of dementia by looking out for such conditions.
Photo Illustration by Thomas Levinson/The Daily Beast/GettyA mild case of COVID for many people resembles a cold, a comforting illusion that President Joe Biden’s recent bout with the virus reinforced even when another positive test returned him to quarantine. And yet, for all the happy talk, the virus continues to remind us that it can wreak havoc on relatively young, healthy people.This is the story of a 49-year-old former Navy SEAL—still in top shape—who tested positive for COVID on the secon
As the monkeypox outbreak in the U.S. continues to spread, demand for the vaccine is outpacing supply. According to a Washington Post article, no more shots are scheduled to arrive until October at the earliest, putting tens of thousands of high-risk men at risk. National reporter Dan Diamond authored that piece and joins CBS News' Lana Zak to discuss.

source


Leave a Reply

Your email address will not be published.